Sisram Medical Ltd (SRAMF) Fair Value & Analysis
Healthcare · US · Market cap $205M
Fair value as of: Jun 25, 2026
Analysis
Sisram Medical Ltd (SRAMF) currently trades at $0.4383, while our model-based Fair Value estimate is $0.8900 — implying the stock looks roughly 103.1% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment, stretch marks, vascular and pigmented lesions, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodeling, injectables, personal care, aesthetic dentistry, hydradermabrasion, blepharoplasty (nonsurgical eyelid lift), liposuction, feminine health, and sexual rehabilitation. It also engages in pharmaceutical research and development activities. The company offers its products under the Alma, LMNT, Copulla, P…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sisram Medical Ltd (SRAMF) undervalued?
What is the fair value of SRAMF?
What is the quality score of SRAMF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.